VEGF-based Targeted Imaging of Tumor Vasculature

基于 VEGF 的肿瘤脉管系统靶向成像

基本信息

  • 批准号:
    7271615
  • 负责人:
  • 金额:
    $ 54.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-02-08 至 2009-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The overall goal of this project is to develop targeted probes for imaging receptors for vascular endothelial growth factor (VEGF) in tumor angiogenesis. Overexpressed VEGF receptors play the crucial role in the onset and progression of tumor angiogenesis and therefore, these receptors are the primary targets of tremendous efforts to develop inhibitors of angiogenesis. However, these receptors are not being used as biomarkers in prescribing or monitoring anti-angiogenic therapy, because there are no non-invasive methods for assessment of their prevalence. Thus, non-invasive imaging of VEGF receptors addresses unmet clinical needs and might lead to evidence-based selection of patient for anti-angiogenic therapy, and design of personalized treatment regiments. In addition, since VEGF receptors are reportedly overexpressed in tumor and contiguous host vasculature at the onset of malignant growth, VEGF receptor imaging might be used for early diagnostics and discrimination between benign and malignant lesions. In Phase I of this project we have developed novel VEGF-based probes for near-infrared fluorescent (NIRF) and single photon emission computed tomography (SPECT) imaging of VEGF receptors that are suitable for clinical development. Site-specific conjugation of contrast agents to appropriately designed VEGF yielded probes that bind to VEGF receptors on endothelial cells as effectively as parental VEGF. We established that our VEGF-based probes undergo receptor-mediated internalization and accumulate in tumor and host endothelial cells overexpressing VEGF receptors. Importantly, using inactivated VEGF-based probes that lost the ability to bind to VEGF receptors, we evaluated a contribution of non-specific mechanisms to probe accumulation in tumor vasculature. Our targeted imaging probes are based on a novel single-chain (sc) VEGF that provides fora significant improvement in expression, refolding, and purification, relative to a conventional VEGF with two subunits linked via disulfide bonds. Site-specific conjugation of contrast agents to scVEGF via our proprietary humanized cysteine containig tag (Cys-tag) ensures homogeneity of the imaging probes. Taking together, our Phase I results open the road to clinical development of VEGF-based probes for selective and specific imaging of VEGF receptors in tumor vasculature. In Phase II, we will establish safety of scVEGF-based probes, develop scalable GLP production of conjugates and characterize utility of these probes for predicting/monitoring responses to a specific inhibitor of VEGF receptors and for early diagnostic of malignant lung lesions. We expect that Phase II results will establish scVEGF-based imaging probes as viable candidates for clinical development. In Phase II of this project we will undertake crucial steps in pre-clinical development of novel targeted probes for molecular imaging of specific receptors that play crucial role in the onset and growth of tumor vasculature and are the primary targets for therapeutic development. Results obtained in the Phase I of this project established 1) feasibility of constructing targeted probes, using a novel proprietary technology, and 2) feasibility of obtaining early and dynamic information about the status of these receptors. Thus, clinical development of these targeted imaging probes open new opportunities for evidence-based selection of patients for specific therapeutic treatments, timely monitoring responses to anti-cancer therapies, for early cancer diagnostics, and discrimination between benign and malignant lesions.
描述(由申请人提供):本项目的总体目标是开发肿瘤血管生成中血管内皮生长因子(VEGF)受体成像的靶向探针。过表达的VEGF受体在肿瘤血管生成的发生和发展中起着至关重要的作用,因此,这些受体是开发血管生成抑制剂的巨大努力的主要目标。然而,这些受体没有被用作处方或监测抗血管生成治疗的生物标志物,因为没有非侵入性方法来评估其患病率。因此,VEGF受体的非侵入性成像解决了未满足的临床需求,并可能导致基于证据的抗血管生成治疗患者的选择和个性化治疗方案的设计。此外,由于据报道VEGF受体在恶性生长开始时在肿瘤和邻近宿主脉管系统中过表达,VEGF受体成像可用于早期诊断和良性与恶性病变之间的区分。在该项目的第一阶段,我们开发了新的VEGF为基础的探针,近红外荧光(NIRF)和单光子发射计算机断层扫描(SPECT)成像的VEGF受体,适合于临床开发。造影剂与适当设计的VEGF的位点特异性偶联产生了与内皮细胞上的VEGF受体结合的探针,其与亲本VEGF一样有效。我们确定了我们的基于VEGF的探针经历受体介导的内化,并在过表达VEGF受体的肿瘤和宿主内皮细胞中积累。重要的是,使用失活的基于VEGF的探针,失去了与VEGF受体结合的能力,我们评估了非特异性机制对肿瘤血管系统中探针积累的贡献。我们的靶向成像探针是基于一种新的单链(sc)VEGF,提供了一个显着改善的表达,重折叠,和纯化,相对于传统的VEGF与两个亚基通过二硫键连接。通过我们专有的人源化含半胱氨酸标签(Cys-tag)将造影剂与scVEGF位点特异性缀合,确保成像探针的均一性。总之,我们的I期研究结果为基于VEGF的探针的临床开发开辟了道路,用于肿瘤血管系统中VEGF受体的选择性和特异性成像。在第二阶段,我们将建立安全的scVEGF为基础的探针,开发可扩展的GLP生产的共轭物和表征这些探针的效用,用于预测/监测反应的特异性抑制剂的VEGF受体和早期诊断恶性肺病变。我们预计,第二阶段的结果将建立scVEGF为基础的成像探针作为可行的候选人的临床开发。在该项目的第二阶段,我们将在临床前开发用于特异性受体分子成像的新型靶向探针方面采取关键步骤,这些受体在肿瘤血管的发生和生长中起着关键作用,并且是治疗开发的主要靶标。该项目第一阶段获得的结果确定了1)使用新的专有技术构建靶向探针的可行性,以及2)获得有关这些受体状态的早期和动态信息的可行性。因此,这些靶向成像探针的临床开发为基于证据选择患者进行特定治疗、及时监测对抗癌疗法的反应、早期癌症诊断以及区分良性和恶性病变提供了新的机会。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph M Backer其他文献

Joseph M Backer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph M Backer', 18)}}的其他基金

Clinical development of 18F PET tracer for imaging VEGF receptors
用于 VEGF 受体成像的 18F PET 示踪剂的临床开发
  • 批准号:
    8648418
  • 财政年份:
    2014
  • 资助金额:
    $ 54.52万
  • 项目类别:
Clinical development of 18F PET tracer for imaging VEGF receptors
用于 VEGF 受体成像的 18F PET 示踪剂的临床开发
  • 批准号:
    9017150
  • 财政年份:
    2014
  • 资助金额:
    $ 54.52万
  • 项目类别:
Targeted photoacoustic imaging of VEGF receptors in angiogenic vasculature
血管生成血管系统中 VEGF 受体的靶向光声成像
  • 批准号:
    8126616
  • 财政年份:
    2011
  • 资助金额:
    $ 54.52万
  • 项目类别:
Targeted delivery of Lu-177 to tumor vasculature
将 Lu-177 靶向递送至肿瘤脉管系统
  • 批准号:
    8332296
  • 财政年份:
    2011
  • 资助金额:
    $ 54.52万
  • 项目类别:
Targeted delivery of Lu-177 to tumor vasculature
将 Lu-177 靶向递送至肿瘤脉管系统
  • 批准号:
    8204231
  • 财政年份:
    2011
  • 资助金额:
    $ 54.52万
  • 项目类别:
Targeted delivery of Lu-177 to tumor vasculature
将 Lu-177 靶向递送至肿瘤脉管系统
  • 批准号:
    7745604
  • 财政年份:
    2009
  • 资助金额:
    $ 54.52万
  • 项目类别:
Targeting anti-apoptotic drugs to failing cardiomyocytes
将抗凋亡药物靶向衰竭的心肌细胞
  • 批准号:
    7271618
  • 财政年份:
    2007
  • 资助金额:
    $ 54.52万
  • 项目类别:
VEGF-driven PET imaging of tumor angiogenesis
VEGF 驱动的肿瘤血管生成 PET 成像
  • 批准号:
    7327851
  • 财政年份:
    2007
  • 资助金额:
    $ 54.52万
  • 项目类别:
Molecular Targeted Imaging in Colon Cancer
结肠癌的分子靶向成像
  • 批准号:
    7405731
  • 财政年份:
    2007
  • 资助金额:
    $ 54.52万
  • 项目类别:
VEGF-based targeted imaging of tumor vasculature
基于 VEGF 的肿瘤脉管系统靶向成像
  • 批准号:
    6882122
  • 财政年份:
    2005
  • 资助金额:
    $ 54.52万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 54.52万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 54.52万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.52万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.52万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.52万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 54.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 54.52万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 54.52万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 54.52万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 54.52万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了